Projected returns on investment in research and development (R&D) for 15 global pharmaceutical companies – including the 12 largest by market capitalisation – have risen to 7.0 per cent in 2021, the highest level since 2014 (7.2 per cent), according to research by Deloitte’s Centre for Health Solutions. This is an increase of 4.3 percentage... Read more »

The post Deloitte’s research finds pharma R&D return on investment rises to highest level since 2014 appeared first on Lifescience Industry News.